Home / Specialty Pharmacy (page 2)

Specialty Pharmacy

FDA Grants Breakthrough Device Designation to C2N Diagnostics’ Blood Test to Screen for Alzheimer’s Disease Risk

ST. LOUIS–(BUSINESS WIRE)–C2N Diagnostics today announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for C2N’s proprietary brain amyloidosis blood test. This test will be used to screen for brain amyloid pathology in individuals being assessed for an Alzheimer’s Disease diagnosis. To qualify for …

Read More »

CVS Health Reaches Pharmacy Benefits Management System Deal with Walmart After Impasse

WOONSOCKET, R.I. and BENTONVILLE, Ark., Jan. 18, 2019 /PRNewswire/ — CVS Health (NYSE: CVS) and Walmart (NYSE: WMT) today announced the companies have reached a multi-year agreement on terms under which Walmart will continue participating in the CVS Caremark pharmacy benefit management (PBM) commercial and Managed Medicaid retail pharmacy networks. The companies are not …

Read More »

Acorda Announces The Lancet Neurology Publication of Phase 3 Data for Inbrija in Patients with Parkinson’s Disease

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that The Lancet Neurologypublished results from SPAN℠-PD, the Phase 3 pivotal efficacy trial of INBRIJA™ (levodopa inhalation powder), also referred to as CVT-301. In the study, INBRIJA 84 mg significantly improved motor function at 30 minutes during OFF periods in people with Parkinson’s taking …

Read More »

ZappRx and Bayer Partner to Improve Access to Specialty Medications

BOSTON–(BUSINESS WIRE)–ZappRx, a digital health company that streamlines the complex processes associated with prescribing specialty medications, announced an agreement with Bayer to provide a more efficient approach to the accessing of specialty medications and associated support programs. ZappRx will support patients living with two specific types of Pulmonary Hypertension (PH) and patients …

Read More »

FDA Grants Breakthrough Therapy Designation to Novartis’ Crizanlizumab for the Prevention of Vaso-Occlusive Crises in Sickle Cell Disease

Basel, January 8, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD). Also known as sickle cell pain crises, VOCs are unpredictable and extremely …

Read More »

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

UG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the treatment of sickle cell disease (SCD). CTX001 is an investigational, autologous, …

Read More »

Horizon Pharma and HemoShear Therapeutics Enter Exclusive Drug Discovery Collaboration in Gout

DUBLIN & CHARLOTTESVILLE, Va.–(BUSINESS WIRE)–Horizon Pharma plc (Nasdaq: HZNP) and HemoShear Therapeutics, LLC, a privately held biotechnology company, today announced a collaboration to discover and develop novel therapeutics for gout. “As we continue to grow our pipeline, we are committed to addressing unmet treatment needs for people with gout as …

Read More »

Better Mouse Model Built to Enable Precision-Medicine Research for Alzheimer’s

Incorporating genetic diversity into a mouse model of Alzheimer’s disease resulted in greater overlap with the genetic, molecular and clinical features of this pervasive human disease, according to a study funded by the National Institute on Aging (NIA), part of the National Institutes of Health. The study also suggests that …

Read More »

FDA Approves Acorda’s Inbrija for Intermittent Treatment of OFF Episodes in Patients with Parkinson’s Disease

ARDSLEY, N.Y.–(BUSINESS WIRE)–Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa. OFF episodes, also known as OFF periods, are defined as the return of Parkinson’s symptoms that result from low …

Read More »

Cigna Completes Combination with Express Scripts, Establishing a Blueprint to Transform the Health Care System

BLOOMFIELD, Conn.–(BUSINESS WIRE)–Cigna Corporation (NYSE: CI), a leading global health service company, has successfully completed its combination with Express Scripts Holding Company (“Express Scripts”) effective December 20, 2018. Consistent with its commitment to support local communities and improve societal health, Cigna also announced an incremental investment of $200 million to …

Read More »